Navigation Links
Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting
Date:5/9/2013

MORAGA, Calif., May 9, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans , Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, gave a presentation at the American Pain Society (APS) 32nd Annual Scientific Meeting on May 8th, 2013, in New Orleans, Louisiana.   

Dr. Yeomans was selected by the APS to present data on Trigemina's lead product candidate, TI-001, an intranasal oxytocin pain therapy, during the Clinical and Basic Science Data Blitz event on Wednesday, May 8th, from 6 PM to 8 PM ET.  The blitz was composed of innovative and compelling presentation of new research, with presenters having five minutes to present and an additional five minutes to answer questions from the audience.

"The need to share and discuss new research in pain has become increasingly important, especially when considering the impact that prescription drug abuse has had on our country in recent years," said Dr. Yeomans. "The APS Data Blitz provides researchers and physicians with valuable information on emerging therapies, like TI-001, which may one day provide a safe, non-addictive and effective solution to people suffering from chronic pain."

TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.  

About Trigemina
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.

For additional information, please visit www.trigemina.com

Contact:

The Ruth Group
Aaron Estrada (media)
aestrada@theruthgroup.com  
(646) 536-7028

Trigemina
Charles Yeomans
cyeomans@trigemina.com
(925) 377-0664


'/>"/>
SOURCE Trigemina, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trigemina to Present at the 2013 BIO International Convention
2. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
3. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
4. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
5. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
6. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show
9. Oracle’s Value Chain Summit San Francisco: Track Sponsor NexInfo presents more industry specific solutions
10. Fertility Associates of Memphis, World-Renowned Expert in Infertility, Presents Findings to European Conference
11. BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, ... Actuator with a flexure design that ensures high alignment accuracy by preventing unwanted ... is ideally suited where extreme precision is required, such as in medical equipment, ...
(Date:11/30/2016)... Fla. , Nov. 30, 2016 Biotest ... products, is pleased to announce the addition of its ... Kearney, Nebraska . The 15,200 square ... on November 29th, 2016 and brings the total number ... Ileana Carlisle , BPC,s Chief Executive Officer ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... 2016 Nearly one billion matches per second with ... ... DERMALOG is Germany's largest ... Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System ...
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
Breaking Biology News(10 mins):